Cellbion
308430
Company Profile
Business description
Cellbion is a radiopharmaceutical innovation engaged in the development and commercialization of radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology. Its pipeline products targeted indications are Prostate Cancer radiotherapy, Solid Tumors Diagnosis, Multiple Cancer types, and Others.
Contact
103, Daehak-ro
6th Floor
Jongno-gu
Seoul03080
KORT: +82 27433311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,818.28 | 32.15 | -0.41% |
| DAX 40 | 24,295.93 | 55.11 | 0.23% |
| Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
| FTSE 100 | 9,138.37 | 76.88 | 0.85% |
| HKSE | 25,667.18 | 129.11 | 0.51% |
| NASDAQ | 21,057.96 | 37.94 | 0.18% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,363.35 | 4.44 | 0.07% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |